Invitrogen™ ApoA2 Recombinant Rabbit Monoclonal Antibody (43H22L4)

Description

This antibody is predicted to react with non-human primate and mouse based on sequence homology. Intact IgG appears on a non-reducing gel as ~150 kDa band and upon reduction generating a ~25 kDa light chain band and a ~50 kDa heavy chain. Recombinant rabbit monoclonal antibodies are produced using in vitro expression systems. The expression systems are developed by cloning in the specific antibody DNA sequences from immunoreactive rabbits. Then, individual clones are screened to select the best candidates for production. The advantages of using recombinant rabbit monoclonal antibodies include: better specificity and sensitivity, lot-to-lot consistency, animal origin-free formulations, and broader immunoreactivity to diverse targets due to larger rabbit immune repertoire.

At least 9 distinct polymorphic forms of apolipoproteins are known. The apolipoproteins act as stabilizers of the intact lipoprotein particles. Quantitative measurements of HDL, LDL, and VLDL particles of human serum are often used to estimate an individual's relative risk of coronary heart disease. In addition, quantitative immunological measurements of certain apolipoproteins ( especially A-1 and B) have been suggested to be more accurate estimators of coronary heart disease that measurements of lipoprotein particles (especially HDL and LDL). The apolipoproteins are derived from human plasma by density gradient ultracentrifugation and HPLC.